Athira Pharma Lays Off 70% of Workforce, Cuts $13.4M Annually Amid Failed Alzheimer’s Trial and Restructuring

Seattle-based biotech Athira Pharma is laying off 49 employees, about 70% of its workforce, as part of restructuring and cost-cutting after unsuccessful Phase 2/3 trial results. The company aims to focus on its ALS treatment ATH-1105 and expects to save $13.4 million annually, with leadership changes effective October 1.